Skip to content
ChickenStockChickenStock
ResearchFilings

AI English summary of an SEC filing — figures as filed

Zimmer Biomet logoZimmer Biomet ZBH

The company said its wholly owned subsidiary Zimmer, Inc. entered into a merger agreement with Paragon 28, Inc., under which each Paragon 28 common share will be converted into $13.00 in cash and one contingent value right (CVR) 1 on January 28, 2025.

8-KRegulation FD DisclosureFiled Period of report Summary published (UTC)

Key points

AI summary
  1. The company said its wholly owned subsidiary Zimmer, Inc. entered into a merger agreement with Paragon 28, Inc., under which each Paragon 28 common share will be converted into $13.00 in cash and one contingent value right (CVR) 1 on January 28, 2025.

  2. The company said the equity value of the Paragon 28 acquisition is about $1.1 billion and the enterprise value is about $1.2 billion. The CVR will be paid at $0.00 to $1.00 per share, calculated on a straight-line basis, if net sales for fiscal 2026 are between $346 million and $361 million.

  3. The company said Paragon 28 announced full-year 2024 net revenue of $255.9 million to $256.2 million. It also said that, considering the impact of financing, the transaction will be about 3% dilutive to adjusted EPS in 2025 and about 1% dilutive in 2026, and accretive to adjusted EPS within 24 months of closing.

  4. The company said it plans to fund the acquisition with cash on its balance sheet and other available debt financing sources. It said closing is subject to regulatory approvals, approval by Paragon 28 stockholders and other conditions, and is expected in the first half of 2025.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Zimmer Biomet Signs Merger Agreement for Paragon 28 at $13.00 Cash Plus CVR

The company said its wholly owned subsidiary Zimmer, Inc. entered into a merger agreement with Paragon 28, Inc., under which each Paragon 28 common share will be converted into $13.00 in cash and one contingent value right (CVR) 1 on January 28, 2025.

Source · Based on the filing body and exhibits

Deal Valued at About $1.1 billion with CVR Payment Terms

The company said the equity value of the Paragon 28 acquisition is about $1.1 billion and the enterprise value is about $1.2 billion. The CVR will be paid at $0.00 to $1.00 per share, calculated on a straight-line basis, if net sales for fiscal 2026 are between $346 million and $361 million.

Source · Based on the filing body and exhibits

Paragon 28 2024 Net Sales and Company's Adjusted EPS Impact

The company said Paragon 28 announced full-year 2024 net revenue of $255.9 million to $256.2 million. It also said that, considering the impact of financing, the transaction will be about 3% dilutive to adjusted EPS in 2025 and about 1% dilutive in 2026, and accretive to adjusted EPS within 24 months of closing.

Source · Based on the filing body and exhibits

Funding Plan and Closing Conditions

The company said it plans to fund the acquisition with cash on its balance sheet and other available debt financing sources. It said closing is subject to regulatory approvals, approval by Paragon 28 stockholders and other conditions, and is expected in the first half of 2025.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

Source: SEC EDGAR (U.S. Securities and Exchange Commission). Item captions are the SEC's. The summary is for reference only and is not investment advice.